Multiple Myeloma

Telehealth and Treatment Selection: Highlights From an Expert Panel on Multiple Myeloma

Ashley E. Rosko, MD, recaps a recent panel discussion on treatment options for multiple myeloma, and discusses the disease space more generally.

A Satellite Sessions program panel at the University of Texas MD Anderson Cancer Center discusses topics in multiple myeloma including the selection of triplet vs quadruplet treatment regimens and optimizing outcomes in the maintenance setting.

Krina K. Patel, MD;Sairah Ahmed, MD;Tejo N. Musunuru, MD ;Melody R. Becnel, MD

Administering Step-up and Treatment Doses of Bispecifics in Patients With MM

A Satellite Sessions program panel at the University of Texas MD Anderson Cancer Center discusses topics in multiple myeloma including the selection of triplet vs quadruplet treatment regimens and optimizing outcomes in the maintenance setting.

Cesar Rodriguez, MD;Scott A. Soefje, PharmD;Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC;Frances A. Bell, NP

Insights from Experts at Mayo Clinic: Sequencing Therapies in MM

Frances A. Bell, NP, leads a conversation on key steps taken leading up to the initial administering of bispecific therapy in patients with multiple myeloma.

Rafael Fonseca, MD;Shaji Kumar, MD, Mayo Clinic;Joselle Cook, MBBS, Mayo Clinic;Morie A. Gertz, MD, MACP, Mayo Clinic

Where Do Bispecifics Fit in the Multiple Myeloma Treatment Paradigm?

Comprehensive insights from experts in Mayo Clinic on the selection and sequencing of CAR T cell therapy or bispecifics, respectively, in patients with relapsed/refractory multiple myeloma.

Cesar Rodriguez, MD;Scott A. Soefje, PharmD;Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC;Frances A. Bell, NP

Other Bispecifics in Development for Multiple Myeloma

Shared insight on the role bispecifics will play in multiple myeloma management as other novel agents and clinical trials continue to enter the landscape.

Rafael Fonseca, MD;Shaji Kumar, MD, Mayo Clinic;Joselle Cook, MBBS, Mayo Clinic;Morie A. Gertz, MD, MACP, Mayo Clinic

Assessing and Treating Patients with High-Risk NDMM

Before closing out the panel’s review of clinical data behind bispecifics in relapsed/refractory multiple myeloma, Morie Gertz, MD, highlights use of cevostamab therapy in this setting.

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

June 19th 2023

Elan Gorshein, DO, JD, MPH, describes potential approaches to managing high-risk patients with transplant-eligible NDMM.

Exploring the GMMG-CONCEPT Study in Patients With Transplant-Eligible NDMM

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

June 19th 2023

Noffar Bar, MD, explains the GMMG-CONCEPT trial in patients with transplant-eligible NDMM.

Multiple Myeloma: An Evolving Treatment Landscape

Krina K. Patel, MD;Sairah Ahmed, MD;Melody R. Becnel, MD ;Tejo N. Musunuru, MD

June 19th 2023

Closing out their discussion on multiple myeloma, expert panelists share expectations and hopes for the future treatment paradigm.

Transplant-Eligible NDMM: Selecting Induction Therapy Based on Risk Status

Andrew P. Dalovisio, MD;Kelly Pippin, MD;Ryan P. Griffin, MD;Ernest C. Quintin, MD;Thomas Atkinson, MD

Patient Profile 3: A 58-Year-Old with IgG Kappa Multiple Myeloma

In the setting of transplant-eligible newly diagnosed multiple myeloma, expert panelists consider how risk status may affect the selection of induction therapy.

C. Ola Landgren, MD, PhD;Dickran Kazandjian, MD;Benjamin Diamond, MD;Dennis Verducci, APRN

Key Updates from the GRIFFIN Trial in Multiple Myeloma

Experts present the case of a 58-year-old patient with IgG kappa multiple myeloma and offer their initial impressions.

Al-Ola Abdallah, MD;Leyla O. Shune, MD;Nausheen Ahmed, MD;Jordan Snyder, PharmD

Patient Profile 1: A 45-Year-Old with Transplant-Eligible Multiple Myeloma

Experts on multiple myeloma discuss recent updates from the GRIFFIN trial on patients with transplant-eligible multiple myeloma.

Al-Ola Abdallah, MD;Leyla O. Shune, MD;Nausheen Ahmed, MD;Jordan Snyder, PharmD

Quadruplet Induction Therapy in Patients With Transplant-Eligible NDMM

A panel of clinical experts presents the case of a patient with high-risk multiple myeloma (MM) who underwent transplant.

Andrew P. Dalovisio, MD;Kelly Pippin, MD;Ryan P. Griffin, MD;Ernest C. Quintin, MD;Thomas Atkinson, MD

Treatment Duration and Maintenance Therapy in NDMM

Shared insight on the advent of quadruplet therapy regimens in the induction setting of transplant-eligible newly diagnosed multiple myeloma.

C. Ola Landgren, MD, PhD;Dickran Kazandjian, MD;Benjamin Diamond, MD;Dennis Verducci, APRN

Updates on Bispecific T-Cell Engager (BiTE) Antibodies in Relapsed Multiple Myeloma

Clinical insights on treatment duration and the decision to place patients with newly diagnosed MM on maintenance therapy.

Ashley Rosko, MD;Naresh Bumma, MD;Abdullah Khan, MBBS;April Logue, APRN-CNP;Barry Hammer, PA-C

June 15th 2023

Abdullah Khan, MBBS, explains the current data on bispecific T-cell engaging antibodies for the treatment of relapsed multiple myeloma.

Available Treatment Options for Patients with Relapsed Multiple Myeloma

Ashley Rosko, MD;Naresh Bumma, MD;Abdullah Khan, MBBS;April Logue, APRN-CNP;Barry Hammer, PA-C

June 15th 2023

Ashley Rosko, MD, presents the case of a 72-year-old woman with relapsed multiple myeloma for discussion.

Treatment Options for Patients with Disease Progression on BCMA-Targeting Bispecifics

Surbhi Sidana, MD;Melissa Alsina, MD; Maria-Victoria Mateos, MD, PhD;Jack Khouri, MD

Step-up Dosing and Monitoring in Patients with MM on Bispecifics: Health System Perspectives

The panel discusses how they would approach the treatment of a patient with relapsed/refractory MM who progresses on BCMA-targeting bispecifics.

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD

Incorporating Teclistamab in R/R MM: Insights from Clinical Practices Across the US

The panel discusses the approach to step-up and treatment dosing for bispecifics in their respective health care systems.

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD

Managing Hematological Toxicities Associated with Bispecifics in MM

Expert hematologist-oncologists discuss how they incorporate teclistamab in their clinical practice as well as variations in access to bispecifics and CAR T-cell therapy.

Saad Z. Usmani, MD, MBA, FACP;Carlyn Tan, MD;Michael Scordo, MD;Anna Howard, RN

Patient Case 2: A 39-Year-Old with Progressive Disease After Initial Response to Teclistamab

Experts on multiple myeloma provide insights on the management of hematological toxicities associated with bispecific antibodies.

Surbhi Sidana, MD;Melissa Alsina, MD; Maria-Victoria Mateos, MD, PhD;Jack Khouri, MD

Treatment Considerations With Bispecifics in Multiple Myeloma

Melissa Alsina, MD, presents the case of a 39-year-old patient with multiple myeloma who has disease progression after initially responding to teclistamab.

Cesar Rodriguez, MD;Scott A. Soefje, PharmD;Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC;Frances A. Bell, NP

Multiple Myeloma: Overview of an Evolving Treatment Landscape

Panelists provide a broad-view perspective on established treatment pathways with bispecifics in multiple myeloma and the most prevalent challenges tied to this class of therapy.

Cesar Rodriguez, MD;Scott A. Soefje, PharmD;Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC;Frances A. Bell, NP

FDA Grants Fast Track Designation to Inobrodib in R/R Multiple Myeloma

Moderator Cesar Rodriguez, MD, spearheads a discussion on the current state of the multiple myeloma treatment paradigm with a focus on bispecifics in the multiply relapsed setting.

$Inobrodib is under investigation as a treatment for patients with relapsed/refractory multiple myeloma and other hematologic malignancies in a phase 1/2a trial.$

Russ Conroy

MonumenTAL-1: Data Updates of Non-BCMA Bispecifics in MM

Inobrodib is under investigation as a treatment for patients with relapsed/refractory multiple myeloma and other hematologic malignancies in a phase 1/2a trial.

Rafael Fonseca, MD;Shaji Kumar, MD, Mayo Clinic;Joselle Cook, MBBS, Mayo Clinic;Morie A. Gertz, MD, MACP, Mayo Clinic